SCHEMBL20178609

SCHEMBL20178609

CCc1ccc(C(=O)OC)c(-c2cccnc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.52
NR4A2 P43354 3/20 0.50
CYP11B1 P15538 2/20 0.49
CYP11B2 P19099 2/20 0.49
SLC2A1 P11166 1/20 0.49
CYP19A1 P11511 1/20 0.49
ALDH1A1 P00352 2/20 0.48
GABRA1 P14867 1/20 0.47
GABRG2 P18507 1/20 0.47
GABRB3 P28472 1/20 0.47
GABRA3 P34903 1/20 0.47
GABRA2 P47869 1/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 2/20 0.47
MKNK1 Q9BUB5 3/20 0.46
MKNK2 Q9HBH9 3/20 0.46
HSD17B10 Q99714 2/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20178622 0.86 KMO (0.47) ALDH1A1MKNK1MKNK2NPC1RAB9A
SCHEMBL28565657 0.84 GABRA1 (0.49) ALDH1A1GABRA1GABRG2GABRB3GABRA3
SCHEMBL20118979 0.83 CYP46A1 (0.56) CFTRNR4A2CYP11B1CYP11B2SLC2A1
SCHEMBL3515912 0.82 CFTR (0.53) CFTRNR4A2CYP11B1CYP11B2SLC2A1
SCHEMBL3515844 0.82 NR4A2 (0.57) CFTRNR4A2CYP11B1CYP11B2SLC2A1
SCHEMBL6777428 0.82 KMT2A (0.49) CFTRCYP11B1CYP11B2SLC2A1ALDH1A1
SCHEMBL3517564 0.81 CYP11B1 (0.55) CFTRNR4A2CYP11B1CYP11B2SLC2A1
SCHEMBL6778188 0.81 FNTA (0.54) CYP11B1CYP11B2GABRA1GABRG2GABRB3
SCHEMBL6777180 0.81 PDE4B (0.55) ALDH1A1KMT2AHSD17B10RAB9AKDM4E
SCHEMBL5859201 0.81 SLC2A1 (0.45) CFTRNR4A2CYP11B1CYP11B2SLC2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 CFTR 32/4885NR4A2 585/4885CYP11B1 268/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 CFTR 32/4885NR4A2 585/4885CYP11B1 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.